Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Br J Haematol. 2018 May;181(3):350-359. doi: 10.1111/bjh.15190. Epub 2018 Apr 2.

Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries.

Author information

1
Haematology, Hospital Universitario de Salamanca, Salamanca, Spain.
2
Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
3
Haematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
4
Service d'Hematologie, St Louis, assistance publique hôpitaux de Paris and Paris Diderot University, Paris, France.
5
Maladies du Sang, Hopital Huriez, CHRU de Lille, Lille, France.
6
Haematology, Hospital Universitario Central de Asturias, Oviedo, Spain.
7
Haematology, CHU Purpan, Toulouse, France.
8
Haematology, Hospital Sanchinarro Norte, Madrid, Spain.
9
Haematology department, Institut Paoli Calmettes, Marseille, France.
10
Hospital Sont Llatzer, Palma de Mallorca, Spain.
11
Haematology, Clinique Universitaire d'Hématologie, CHU de Grenoble, Grenoble, France.
12
Hospital 12 de Octubre, Madrid, Spain.
13
Unité de Recherche Clinique, Service d'Hématologie Clinique et Thérapie Cellulaire, Limoges, France.
14
Hospital Puerta del Mar, Cadiz, Spain.
15
Service d'hématologie et thérapie cellulaire, CHRU de Tours, Team 3 UMR CNRS 7292, Université François Rabelais, Tours, France.
16
Hématologie - Hôpital Bon Secours, Metz-Thionville, Thionville, France.
17
Hematologie, Institut Gustave Roussy, Villejuif, France.
18
Haematology Department, Hôpital Civil, Strasbourg, France.
19
Haematology Department, Centre Henri Becquerel, Rouen, France.
20
Haematology Department, CHU de Nantes, Nantes, France.
21
Hôpital de Corbeil, Corbeil, France.
22
Department of Haematology, Assistance Publique-Hopitaux de Paris (AP-HP) Saint-Antoine, Universite Pierre et Marie Curie, Paris, France.
23
Hematologie, CHU Estaing, Clermont-Ferrand, France.
24
Department of application statistics, Universidad Autónoma de Barcelona, Barcelona, Spain.

Abstract

Treatment with azacitidine (AZA) has been suggested to be of benefit for higher-risk myelodysplastic syndrome (HR-MDS) patients with chromosome 7 abnormalities (Abn 7). This retrospective study of 235 HR-MDS patients with Abn 7 treated with AZA (n = 115) versus best supportive care (BSC; n = 120), assessed AZA treatment as a time-varying variable in multivariable analysis. A Cox Regression model with time-interaction terms of overall survival (OS) at different time points confirmed that, while chromosome 7 cytogenetic categories (complex karyotype [CK] versus non-CK) and International Prognostic Scoring System risk (high versus intermediate-2) retained poor prognosis over time, AZA treatment had a favourable impact on OS during the first 3 years of treatment compared to BSC (Hazard ratio [HR] 0·5 P < 0·001 at 1 year, 0·7 P = 0·019 at 2 years; 0·73 P = 0·029 at 3 years). This benefit was present in all chromosome 7 categories, but tended to be greater in patients with CK (risk reduction of 82%, 68% and 53% at 1, 3 and 6 months in CK patients; 79% at 1 month in non-CK patients, P < 0·05 for all). AZA also significantly improved progression-free survival (P < 0·01). This study confirms a time-dependent benefit of AZA on outcome in patients with HR-MDS and cytogenetic abnormalities involving chromosome 7, especially for those with CK.

KEYWORDS:

azacitidine; chromosome 7 abnormalities; high risk MDS; time-dependent analysis

PMID:
29611196
DOI:
10.1111/bjh.15190
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center